Michael Landsittel Blueprint Medicines Corp (BPMC) insider trading activity

Michael Landsittel is CHIEF FINANCIAL OFFICER of Blueprint Medicines Corp. Currently has a direct ownership of 72,924 shares of BPMC, which is worth approximately $6.6 Million. The most recent transaction as insider was on Mar 05, 2025, when has been sold 5,284 shares (Common Stock) at a price of $88.8 per share, resulting in proceeds of $469,219. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 72.9K

8.5% 3M change

54.22% 12M change

Total Value Held $6.6 Million

Michael Landsittel Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 05 2025	SELL Open market or private sale	$469,219 $88.8 p/Share	5,284 Reduced 6.76%	72,924 Common Stock
Mar 01 2025	BUY Grant, award, or other acquisition	-	11,000 Added 12.33%	78,208 Common Stock
Aug 15 2024	SELL Open market or private sale	$419,869 $95.23 p/Share	4,409 Reduced 6.16%	67,208 Common Stock
May 15 2024	SELL Open market or private sale	$411,411 $106.86 p/Share	3,850 Reduced 5.1%	71,617 Common Stock
May 08 2024	BUY Exercise of conversion of derivative security	$150,486 $5.34 p/Share	28,181 Added 27.19%	75,467 Common Stock
May 02 2024	SELL Open market or private sale	$1,050,000 $105.0 p/Share	10,000 Reduced 17.46%	47,286 Common Stock
May 02 2024	BUY Exercise of conversion of derivative security	$360,500 $36.05 p/Share	10,000 Added 14.86%	57,286 Common Stock
Mar 28 2024	SELL Open market or private sale	$475,000 $95.0 p/Share	5,000 Reduced 9.56%	47,286 Common Stock
Mar 28 2024	BUY Exercise of conversion of derivative security	$180,250 $36.05 p/Share	5,000 Added 8.73%	52,286 Common Stock
Mar 15 2024	SELL Open market or private sale	$1,209,416 $88.06 p/Share	13,734 Reduced 22.51%	47,286 Common Stock
Mar 15 2024	BUY Exercise of conversion of derivative security	$180,250 $36.05 p/Share	5,000 Added 7.57%	61,020 Common Stock
Mar 07 2024	SELL Open market or private sale	$453,722 $90.69 p/Share	5,003 Reduced 8.2%	56,020 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	12,500 Added 17.0%	61,023 Common Stock
Mar 06 2023	SELL Open market or private sale	$135,615 $45.1 p/Share	3,007 Reduced 5.84%	48,523 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	12,500 Added 19.52%	51,530 Common Stock
Mar 07 2022	SELL Open market or private sale	$58,831 $56.19 p/Share	1,047 Reduced 2.61%	39,030 Common Stock
Mar 03 2022	SELL Open market or private sale	$80,039 $60.27 p/Share	1,328 Reduced 3.21%	40,077 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	12,500 Added 23.19%	41,405 Common Stock
Mar 04 2021	SELL Open market or private sale	$132,315 $87.8 p/Share	1,507 Reduced 4.96%	28,905 Common Stock
Mar 01 2021	BUY Grant, award, or other acquisition	-	13,062 Added 30.05%	30,412 Common Stock

Michael Landsittel

CHIEF FINANCIAL OFFICER

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BPMC shares.

Notify only if

Value

Insider Trading

Get notified when an Blueprint Medicines Corp insider buys or sells BPMC shares.

Notify only if

Operation

Value

Type

News

Receive news related to Blueprint Medicines Corp

Track Activities on BPMC

Account